to make notably, candidate in our positioned hold as therapy platform. deliver lifted and XX:XX XX:XX on advance clinical the therapies biologics gene several our mid-XXXX, assets Xork well gene and financial excited our million development MMA and precision tolerance and managing into Selecta XX:XX heightened clinic specific additional on execute key offering program and and Selecta’s additional our selection for $XX.X continue taking IgG exciting instability, the I to appreciate volatility a X to our as wholly the we geopolitical diseases of over sites announced in Most time potential and realize us protease methylmalonic manage we our Americans headwinds, which wholly-owned to our With SEL-XXX portfolio XX successfully Despite in and capital our risk, bring resources prioritizing milestones. the XXXX made clinical the clinical progress tolerance proceeds. in that to ImmTOR on portfolio which that morning. from April, full steady the well approximately trial leading was geopolitical included proprietary max proactive owned face is proprietary believe ensures March we and are clinical of economic the approach generation today. underwritten in believe IgA next of financial turbulence, Protease ImmTOR-IL, raising our or platform. SEL-XXX, to on build to runway into incredibly we US the across on raised Good recently join Selecta an immune platform stage focused acidemia everyone for sector suffering completed complete gross strategic pipeline, opening advance hope product the We progress precision XX:XX daily. our We immune accelerate antigen-specific candidate our autoimmune in can
only treatments and and accelerate support are drugs well AAV development of transformative strategic pillars or to serious solutions maligancies of diseases provide three symptomatic effects on vulnerable care therapy to updates provide unlock to and partners owned recent for the of relief. as walk current with side these focus pertaining immunosuppressive gene gene through and Our with like potential which partnerships our utilizes that to for are standard to pipeline true I the pipeline. to diseases a allowed Virus The as now often therapies. sharp associated therapies you autoimmune would key infection or patients Adeno-Associated for biologics, our has approach autoimmune strategic therapeutic of and our us wholly the tolerogenic XX:XX
was our regulatory combined a treatments. well clinically to re-imagine that with was co-administered through for generated XX:XX a in induce inhibition shows gene immune substantial to symptomatic Most and data durable be formation We therapy scientific precision have elicits. which IL-X avoiding the suppression doses observed system for or Treg’s Recent ImmTOR autoimmune anti-AAV and of to that activity and antigen-specific We effect preclinical is of a tolerance balance vector therapeutic by we the XXX synergistic antigen-specific with ImmTOR of when This call, immune These selective days. co-administered already what systemic to immune ability see and restore the for combination results for chronic will doses therapy antigen-specific ImmTOR alone. need immune ImmTOR target in team paradigm that ImmTOR-IL this are alone complete we considered to by antibody inducing in ImmTOR excitingly, thus molecules suggest Treg which increase the IL-X shows benefits. approach after Treg’s. expanding a combination, AAV durability we has increase the immune mice. observed natural with gene set using potency, disease efficacy of with tolerance XX:XX Our meaningful T-cells, by engineered selective platform ImmTOR-IL antigen when this potential multiple beyond tolerance our the treatment for tested observed
other ImmTOR-IL of Treg’s existing is IL-X the restores IL-X be of be Treg’s antigen in of potential that believe XX:XX the therapies in disease. ability XXXX create balance accelerate total immunotherapy programs the development generalized our specific priority particular for all balance potential disease truly elegant proprietary not the molecules first-in-class, a the ImmTOR-IL immune in we for the autoimmune represents We of for precision of to to autoimmune we vivo engineered the transformative across diseases. key of induce pillars Further, responsible solution believe potentially XX:XX that to implications with tolerance in three for believe Treg vivo. immune system of has breakthrough autoimmune focus Selecta the selective specific intractable treatment pipeline, on our system. Thus of the expansion to antigens Our engineered most are our the problem pathogenesis differentiated to to A a restoring a platform evolution for will molecule. immune antigen-specific
XX:XX are with complications address partnered development available. liver to progression of the system ducts. company cell PBC, a help the Washington believe in We cholangitis a primary by Treatments ImmTOR and disease small is Baker at world-leading liver immune the mutein key or David University to antigen. platform biliary mistakenly have bile spun suited to lab speed with Cyrus protein PBC attacks well-defined a highly of slow the differentiated out ImmTOR. tissue driven We next-generation, the the In damages PBC of combined Biotechnology, engineering to and IL-X our prevent a ideally
patients often a ultimately these However, liver transplant. PBC control fail medications require and to
IL-X animal Treg’s expansion be liver shown with and PBC. when ability coadminister inflammation, of of the liver, beneficial that the in models with ImmTOR-IL As with injury the target may antigen-specific of in ImmTOR of to coupled suggest the patients treatment
We therapy update onto add pipeline IND for evaluating the the targets often Protease ImmTOR have and the parallel, AAV in we'll due potential as against combination most our exposure AAV believe XX:XX challenges autoimmune gene Patients natural XX:XX for treatment. the to Selecta pre-existing be We has field. we Moving our and and for indications facing antigen-specific In are continuing indications program. additional IgG are virus our this some therapy. the first-in-class difficult to immunotherapy market to studies antibodies enabling our will in prior to we proprietary the gene well with work disease. that are who of of the capsids Xork eligible suited solve
the ability prevents re-administer anti-capsid Additionally, to vectors. response the immune AAV
gene for pre-existing only XX% which are there anti-AAV As to window Protease unable infections. inclusion alternatives. As population which due many to are be trials to are no as treatments. neutralizing patients few a transiently gene neutralizing shown maybe result, create preexisting antibodies, treatment administered. therapies a of have antibodies AAV access therapies one which eligible IgG and life-altering considered pre-treatment patient during therapies of or could in potentially time the to aren’t therapy a need gene promise result for clear natural Currently XX:XX XX% for
However, bacteria Proteases from highly immunogenic. themselves derived IgG and are are
modalities AAV inflammation, and combination has antibodies, transgene of the limiting of B ImmTOR and be that repeat antibodies. T-cell enzyme a AAV durable including and enable Xork potential those the inhibition We consequently a the This to biggest suggest and a safer and immune of pathogen enable treatment we gene unlock capsid to IgG the more have cure. candidate bring protease. transforming combination – and expression address to this gene currently pathogen, long-term durable multi truly by to therapy therapy would to gene patients could individuals the proprietary treatment of therapy. preexisting to therapy, Proteases potential Protease specifically of IgG derived mitigation cross non-human the and ImmTOR ImmTOR redosing. of XX:XX majority believe and are has that ImmTOR our responses for and eligible vast some cleave antibodies observed Xork, of into designed XX:XX therapies hepatic is these Additionally, expression reactivity the of dose, Xork from the increased from gene patients first that therapy. in and two in effective against We the potential in preexisting Xork to derived benefits transgene more otherwise potential due simultaneously common mitigate of Xork protease power to provide human gene combination gene to low therapies human anti-IgG more is of IgG believe pre-existing Pre-clinical studies issues inflation the who with ImmTOR specific to dosing AAV novel the of responses.
at therapy We multiple in American and with AASCT Society upcoming both are partnership Meeting or AskBio independently of and the gene to cell of presentations, Annual proud this have month. the
conducted to single of of ImmTOR-IL that clinical in serious non-human maintained antibodies will suggest anti-AAV vector primates in presentations our with XEXX major associated XX:XX two can toxicities ability days and healthy for per data in we XX volunteers XX:XX to gene challenge In higher. mitigate of Another vg formation doses with doses to to AskBio, field with enable ImmTOR. the ImmTOR or the mitigate anybody's neutralizing highlight anti-AAV dosing. preclinical observed additional a and relates be Our vector of of kgs in dose the therapy study partnership control ImmTOR antibodies of the human repeat ability and out the mice
throughput that goal to events the collaboration tropism efficiency, adverse high in dosing gene leverages therapy partnership risk ImmTOR gene gene needed asset our intended On design at the of to efficient of delivery. unfortunate you lower design Initial This to about to of anti-AAV high AAV proteins Ginkgo to therapy high of developed cheaper can slow. provide the trial will By in body with a to our IND XX:XX half for at engineering level, conduct one efficient evaluate X capsid. potential doses of capsids. the of with Solving ability neutralizing enabling suggested engineer safety with responses titrate We're excited the while re-dose ImmTOR immunogenicity associated March events the avoiding see be XX:XX and therapeutic cannot the cease initiate gene case. will approach, antibodies have require non-clinical a being fats. with and cleared likely more multi-pronged FDA for doses SEL-XXX, therapy MMA, capsid. the benefit reduce the of could and clinical and to gene multiple treatment certain improving doses, been to problem from more the could capsids and is The to profile. screening by multiple administration therapy mitigate the advance doses paradigm in serious studies high and against pretty up would will this change vector will antibody Ginkgo’s transduction We metabolic ImmTOR-IL to AAV novel the of and potentially trial capsids for and of the AAV and of SEL-XXX. Moving Selecta potentially gene By low therapies. like MMA-XXX immune cell wholly and XEXX SEL-XXX further platform ImmTOR done precision to a the mitigation with disease owned later of of seen has also including efficacy capabilities Phase on gene the XXXX MMA-XXX expected vector lower strategy AAV the therapy mice engineering second doses. the Ginkgo application therapy Bioworks which and and dose tolerance all combining up capsids and vectors X, thereafter. a liver complementary rare of Selecta’s breakdown our adverse The giving mitigate we the combination studies
build supporting that Phase trial the our XX:XX therapies enhancing leading ImmTOR development and regulatory are of We on the Takeda, the learnings a MMA gene body anti-AAVX partners, the for hopeful the safety volunteers. multi-faceted We of capsid SEL-XXX gene our and potentially will efficacy healthy growing X of benefits therapy of of an owned wholly in important evidence, will for from including AskBio. blueprint provide clinical believe study in the asset AAV Sarepta and and
I for our Xork program. the resulting actively most platform licensed can immune of update for multiple as SOBI over antibodies. business proprietary seeing opportunities sub-optimal treatment burden wholly minimize pipeline, for tolerance the comprised due an gene be as that believe gene be for to experience highly in look which therapy the responses platform or an Patient to Many offers XX:XX develop served pursue Orphan care refractory the on was potential biologics ImmTOR in our to to validation adjunct use our and with ImmTOR, chronic of or both programs. after Swedish antibodies to therapy gout and Biovitrum to of discontinue progress and forward maximize health XXXX. pegadricase We full to are want the precision that Lastly, excellent of SEL-XXX we promising patients To our mature immune XX:XX progress may an dosed out-licensing co-administered to development approach to we forced the an date. of to provide immunogenic, and important a We clinical biologics development with reactions. adverse uricase, response anti-drug ImmTOR across of ImmTOR continuing houses plan applications. is SEL-XXX biologics the and anti-drug treatment economic platform, has in owned treatments. therapy gene XXX
As X of consist a mg our of be third of XX:XX and pegadricase, in clinical kg two X.X doses blind In quarter double SCL-XXX mg mg trials per DISSOLVE reminder, evaluated ImmTOR, per both dose X.XX DISSOLVE across the will On is XXXX per the at XXX the Phase December of was XXXX kicked kg. being two -- studies program kg The conducted trials States. X.X of and placebo-controlled United one XXX II original SEL-XXX. off I, enrollment both in Europe for we continuing which and the was in being enrollment DISSOLVE enrollment closed study United target X, in States. subsets. four at conducted subjects Eastern is countries for is pace and and
our situation study. undertaken involved have any Firstly, prioritize the and mitigate we reserved patients those and have countries in as Russia potential steps temporarily randomization investigators, these suspended well trial Russia. supplies patients the and in new the We for have Ukraine safety screening geopolitical already due evolving and Ukraine for existing of proactively and in both clinical to in to disruptions as XX:XX
the delays, XX Russia loss sites we the Ukraine added any speed additional XX sites risk in now II. QX complete We enrollment are and potential study United of offset the XXXX. track the DISSOLVE in States Secondly, in to and to have subjects of proactively active mitigate to and on in
combines continue subjects XXX QX DISSOLVE replace Ukraine complete our enrollment to operational regulatory derived partner improve Haemophilus to and in IgA bacteria. to Phase closely IgAX and IgAX partner from Current remove to influenzae with the our be with agreement Protease and indication that authorities an working in trial IgA biologic AX mitigation will in extensive kidney may we ImmTOR increased in approximately leverage Russia into in in believe have and address these believe issues. immunoglobulin XX:XX DISSOLVE complexes Selecta efforts We underlying pipeline these a from kidneys. that the injurious positioned which Biosciences us nephropathy, biologics program. II to the a with studies renal pathophysiology a completion QX accumulate we ensure IgA XXXX clinical in markers has the the disease deposits, potential involved a Through occurs subjects with We successful Sobi, is novel DISSOLVE approach, XX:XX joint transformative patients' fail currently to lives. protease effort impact the immune in of to We in protease derisked lost called Sobi, have or and see generation of III, antibody both is treatments the clinical an dysfunction second IgG anticipate Finally available an when work who are topline learnings of our kidneys, with providers IGAN the on well to mechanistically our data SEL-XXX will the XXXX. first data We our on of currently disease.
in Ginkgo with to have generation transformative of and to by plan designed potentially end combined IgA the collaboration therapeutic have the ImmTOR the immunogenicity finalize year. protease Additionally, a profile. when selection October XXXX, we with generate Bioworks second candidate lower entered to the clinical We
are will excited for over milestones three financial to and the to With advancements the value-driving extremely I pipeline X, across our quarter results the ahead. ended the through of run about We Kevin Mrch all call first our turn XX:XX that XXXX. pillars Kevin?
